- Advanced Proteome Therapeutics (APC) has closed a non-brokered private placement raising gross proceeds of $72,500.00
- The company issued 1,450,000 shares at a price of $0.05 per share
- The gross proceeds of the offering will be used for general working capital
- Advanced Proteome Therapeutics Corp is a biotechnology company
- Advanced Proteome Therapeutics Corp. (APC) opened trading at C$0.045
Advanced Proteome Therapeutics (APC) has closed a non-brokered private placement raising gross proceeds of $72,500.00.
The company issued 1,450,000 shares at a price of $0.05 per share.
There were no finders’ fees paid in connection with the offering.
All securities issued will be subject to a statutory four-month hold period expiring on April 24, 2023.
The gross proceeds of the offering will be used for general working capital.
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., is developing a proprietary technology to directly target cancerous tumours and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.
Advanced Proteome Therapeutics Corp. (APC) opened trading at C$0.045.